

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2015

PART I													Rs. In Lacs
PART I	Particulars	Standalone					Consolidated						
		Unaudited			Unaudited		Audited	Unaudited			Unaudited		Audited
		Three Months ended 31.12.2015	Preceding Three Months ended 30.09.2015	Corresponding Three Months ended 31.12.2014	Nine Months ended 31.12.2015	Corresponding Nine Months ended 31.12.2014	Previous Year 31.03.2015	Three Months ended 31.12.2015	Preceding Three Months ended 30.09.2015	Corresponding Three Months ended 31.12.2014	Nine Months ended 31.12.2015	Corresponding Nine Months ended 31.12.2014	Previous Year 31.03.2015
1	Income from operations												
	(a) Net sales/income from operations (Net of excise duty)	116.21	273.67	478.76	641.65	1,197.77	1,585.55	1,743.53	1,861.75	2,865.74	5,233.00	7,676.48	10,274.63
	(b) Other operating income	2.63	8.85	10.09	17.43	32.25	77.56	3.91	12.09	10.15	21.95	32.51	81.41
	Total income from operations (net)	118.84	282.52	488.85	659.08	1,230.02	1,663.11	1,747.44	1,873.84	2,875.89	5,254.95	7,708.99	10,356.04
2	Expenses												
	(a) Cost of materials consumed	32.81	151.21	234.96	303.57	579.71	722.45	857.58	983.97	1,717.37	2,639.80	4,636.66	6,326.90
	(b) Purchases of stock-in-trade	8.12	43.10	31.24	59.03	53.99	153.52	8.12	43.10	31.24	59.03	53.99	153.52
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	3.17	40.41	24.79	161.90	155.26	13.76	(14.00)	122.33	45.49	258.46	210.72
	(d) Employee benefits expense	31.08	22.99	85.28	87.24	215.37	284.33	195.76	162.09	209.78	528.54	580.76	771.76
	(e) Depreciation and amortisation expense	14.52	14.51	18.23	43.52	58.82	79.85	70.10	69.78	87.34	209.54	205.27	299.32
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	39.19	56.19	85.97	158.65	216.78	301.67	417.58	372.17	427.67	1,122.98	1,214.77	1,609.91
	Total expenses	125.72	291.17	496.09	676.80	1,286.57	1,697.08	1,562.90	1,617.11	2,595.73	4,605.38	6,949.91	9,372.13
3	Profit / (Loss) from operations before other income, finance costs and exceptional items(1-2)	(6.88)	(8.65)	(7.24)	(17.72)	(56.55)	(33.97)	184.54	256.73	280.16	649.57	759.08	983.91
4	Other Income	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	(6.88)	(8.65)	(7.24)	(17.72)	(56.55)	(33.97)	184.54	256.73	280.16	649.57	759.08	983.91
6	Finance costs	24.85	28.24	31.04	83.36	104.25	141.44	99.82	105.00	113.46	327.61	324.65	439.77
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	(31.73)	(36.89)	(38.28)	(101.08)	(160.80)	(175.41)	84.72	151.73	166.70	321.96	434.43	544.14
8	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	(31.73)	(36.89)	(38.28)	(101.08)	(160.80)	(175.41)	84.72	151.73	166.70	321.96	434.43	544.14
10	Tax Expense	-	0.14	-	0.14	-	(55.62)	-	11.38	-	11.38	-	118.43

	Particulars	Standalone						Consolidated					
		Unaudited			Unaudited			Unaudited			Audited		
		Three Months ended 31.12.2015	Preceding Three Months ended 30.09.2015	Corresponding Three Months ended 31.12.2014	Nine Months ended 31.12.2015	Corresponding Nine Months ended 31.12.2014	Previous Year 31.03.2015	Three Months ended 31.12.2015	Preceding Three Months ended 30.09.2015	Corresponding Three Months ended 31.12.2014	Nine Months ended 31.12.2015	Corresponding Nine Months ended 31.12.2014	Previous Year 31.03.2015
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	(31.73)	(37.03)	(38.28)	(101.22)	(160.80)	(119.79)	84.72	140.35	166.70	310.58	434.43	425.71
12	Extraordinary items (net of tax expense Rs. ___ Lakhs)	-	-	-	-	-	-	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12)	(31.73)	(37.03)	(38.28)	(101.22)	(160.80)	(119.79)	84.72	140.35	166.70	310.58	434.43	425.71
14	Share of Profit / (loss) of associates*	-	-	-	-	-	-	-	-	-	-	-	-
15	Minority Interest *	-	-	-	-	-	-	0.23	0.35	0.41	0.82	1.19	1.09
16	Net Profit / (Loss) after taxes, Minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *	(31.73)	(37.03)	(38.28)	(101.22)	(160.80)	(119.79)	84.49	140.00	166.29	309.76	433.24	424.62
17	Paid-up equity share capital (Face Value of the share Rs. 10)	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	652.70	-	-	-	-	-	2,513.04
19.i	Earning per share (before extraordinary items) (of Rs. 10/-each) (not annualised)												
	(a) Basic	(0.37)	(0.44)	(0.45)	(1.19)	(1.89)	(1.41)	0.99	1.65	1.96	3.64	5.09	4.99
	(b) Diluted	(0.37)	(0.44)	(0.45)	(1.19)	(1.89)	(1.41)	0.99	1.65	1.96	3.64	5.09	4.99
19.ii	Earning per share (after extraordinary items) (of Rs. 10/-each) (not annualised)												
	(a) Basic	(0.37)	(0.44)	(0.45)	(1.19)	(1.89)	(1.41)	0.99	1.65	1.96	3.64	5.09	4.99
	(b) Diluted	(0.37)	(0.44)	(0.45)	(1.19)	(1.89)	(1.41)	0.99	1.65	1.96	3.64	5.09	4.99

Notes:

1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 12, 2016
2	The Statutory Auditors have carried out a 'Limited Review' of the financial results for the quarter and nine months ended 31st December, 2015
3	The Company has opted to submit Standalone as well as Consolidated financial statements. The Consolidated financial results comprise the results of Parnax Lab Limited and One Subsidiary Company
4	Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.
5	The Company has declared layoff in its Silvassa plant due to labour unrest. However, the Company has made alternate arrangements for its export business
6	EPS for quarter ended is on non annualised basis.
7	The Company is dealing into one segment : Dealing in Pharmaceutical Formulations

For Parnax Lab Limited

Whole Time Director